BRCA1 and head and neck cancer: In addition, phenylbutyrate sensitized one head and neck cancer cell line with a defective FA/BRCA1 pathway to cisplatin suggesting that phenylbutyrate targets multiple pathways that normally protect cells against cisplatin.